师资队伍

夏洪平课题组


团队介绍：

重大疾病分子病理免疫与精准诊疗转化医学研究团队依托东南大学医学院/附属中大医院及数字医学工程全国重点实验室和江苏省重症医学重点实验室等平台，聚焦炎症与肿瘤等重大疾病的分子病理免疫基础，通过构建多中心临床-分子病理队列，整合基因组学、蛋白质组学和单细胞空间组学等多维度数据，深度解析炎症与恶性肿瘤复发转移耐药等异质性特征及病理微环境动态演化规律，致力于开发个体化分子诊断与精准诊疗等联合治疗策略，本团队主持和参与国家自然科学基金，科技创新2030四大慢病重大专项和江苏省双创团队等国家及省部级项目6项，在Nature Cancer、Hepatology、Journal of Hepatology、Acta Pharmaceutica Sinica B，ACS Nano和Theranostics等国际权威期刊上发表论文100余篇，申请并已授权国际PCT和国家发明专利多项，计划推进研究者发起的临床研究和多中心临床试验，实现基础研究向临床转化的全链条贯通，与新加坡国立大学和健保集团国立癌症中心等国内外多家高校临床研究机构和生物医药公司建立紧密合作关系，持续推动肿瘤精准诊疗等医学事业发展和临床基础人才培养。


师资队伍：

负责人：夏洪平（教授/主任医师，101013473@seu.edu.cn，江苏省南京市和燕路371号）


研究方向：重大疾病分子病理免疫与精准诊疗转化医学研究


科研进展：开展多临床中心合作，构建不同炎症耐药和消化道肿瘤等临床大队列和疾病细胞与动物模型，深入探讨炎症与肿瘤等重大疾病的分子病理免疫基础特征及其微环境动态演化规律，致力于开发个体化分子诊断与精准诊疗等联合治疗策略。


近五年部分代表性论文：

  1. An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma.  Feng Z, … , Xia H*, Chen X*. Nat Cancer. 2024 Jan;5(1):30-46. doi: 10.1038/s43018-023-00650-8

  2. STK39 inhibits antiviral immune response by inhibiting DCAF1-mediated PP2A degradation. Chengfei Zhang, … , Hongping Xia*,Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2024.12.034

  3. Single-cell landscape identifies the immunophenotypes and microenvironments of HBV-positive and HBV-negative liver cancer. Zheng Q, …, Xia H*. Hepatol Commun. 2024 Jan 22;8(2):e0364.

  4. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer. Yao Z, …, Xia H*. Acta Biomater. 2024;173:365-377.

  5. RHOJ Induces Epithelial-to-Mesenchymal Transition by IL-6/STAT3 to Promote Invasion and Metastasis in Gastric Cancer. Ma Z, …, Xia H*. Int J Biol Sci. 2023 Aug 21;19(14):4411-4426.

  6. Feng Z, ..., Chen X, Xia H*. Exosomal STIMATE derived from type II alveolar epithelial cells controls metabolic reprogramming of tissue-resident alveolar macrophages. Theranostics 2023; 13(3):991-1009.

  7. RhoJ facilitates angiogenesis in glioblastoma via JNK/VEGFR2 mediated activation of PAK and ERK signaling pathways. Wang M, …, Xia H*, Jiang X*. Int J Biol Sci. 2022 Jan 1;18(3):942-955.

  8. Zhang C, …, Xia H*. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway. Theranostics. 2021 Jan 1;11(5):2108-2122.

  9. Feng Z,…,Xia H*. Epithelium- and endothelium-derived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response. Cell Death Differ. 2021;28(7):2238-2256.

  10. The variable association between expression and methylation of estrogen receptors and the survival of patients with different tumors. Hu C, …, Xia H*. Clin Transl Med. 2020;10(2):e49.